Gilead Sciences Stock Forecast, Price & News

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 1 sell rating, 11 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Gilead Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View analyst ratings for Gilead Sciences or view top-rated stocks.

Wall Street analysts have given Gilead Sciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gilead Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Gilead Sciences.

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings data on Thursday, February, 4th. The biopharmaceutical company reported $2.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.15 by $0.04. Gilead Sciences had a trailing twelve-month return on equity of 37.77% and a net margin of 5.48%.
View Gilead Sciences' earnings history.

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GILD shares have decreased by 12.3% and is now trading at $64.62.
View which stocks have been most impacted by COVID-19.

Gilead Sciences declared a quarterly dividend on Thursday, February 4th. Stockholders of record on Monday, March 15th will be given a dividend of $0.71 per share on Tuesday, March 30th. This represents a $2.84 annualized dividend and a yield of 4.39%. The ex-dividend date is Friday, March 12th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.68.
View Gilead Sciences' dividend history.

Gilead Sciences pays an annual dividend of $2.72 per share and currently has a dividend yield of 4.33%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences does not yet have a strock track record of dividend growth. The dividend payout ratio of Gilead Sciences is 44.30%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 38.80% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

Gilead Sciences issued an update on its FY21 earnings guidance on Thursday, February, 4th. The company provided earnings per share (EPS) guidance of $6.75-7.45 for the period, compared to the Thomson Reuters consensus estimate of $6.90. The company issued revenue guidance of $23.70-25.10 billion, compared to the consensus revenue estimate of $24.49 billion.

24 brokerages have issued 1 year price targets for Gilead Sciences' stock. Their forecasts range from $61.00 to $625.00. On average, they anticipate Gilead Sciences' share price to reach $96.04 in the next twelve months. This suggests a possible upside of 48.6% from the stock's current price.
View analysts' price targets for Gilead Sciences or view top-rated stocks among Wall Street analysts.

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR).
View all of GILD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), The Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.87%), Dodge & Cox (1.36%), Northern Trust Corp (1.22%), Bank of New York Mellon Corp (1.10%), Norges Bank (1.05%) and California Public Employees Retirement System (0.81%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences.

GILD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, American International Group Inc., Price T Rowe Associates Inc. MD, First Trust Advisors LP, Renaissance Technologies LLC, PGGM Investments, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Javier Rodriguez, John Francis Cogan, and Merdad Parsey.
View insider buying and selling activity for Gilead Sciences or view top insider-selling stocks.

GILD stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Dodge & Cox, Amundi Pioneer Asset Management Inc., Cibc World Markets Corp, Morgan Stanley, Federated Hermes Inc., KAMES CAPITAL plc, and Assenagon Asset Management S.A..
View insider buying and selling activity for Gilead Sciences or or view top insider-buying stocks.

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GILD stock can currently be purchased for approximately $64.62.

Gilead Sciences has a market capitalization of $81.20 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis.

Gilead Sciences employs 11,800 workers across the globe.

The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, Bristol-Myers Squibb and Gilead Sciences Limited, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland UC, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences llac Ticaret Limited Sirketi, Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, Kite Pharma UK Ltd, MYR, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Tri-Supply Limited, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..

Gilead Sciences was founded in 1987.

The official website for Gilead Sciences is www.gilead.com.

Gilead Sciences is headquartered at 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]